Ignite Creation Date:
2024-05-06 @ 6:44 PM
Last Modification Date:
2024-10-26 @ 2:53 PM
Study NCT ID:
NCT05764590
Status:
COMPLETED
Last Update Posted:
2024-01-10
First Post:
2023-02-17
Brief Title:
A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients
Sponsor:
Alebund Pharmaceuticals
Organization:
Alebund Pharmaceuticals
Study Overview
Official Title:
A Phase 2 Randomized Open-Label Active-Controlled Multicenter Study to Evaluate the Safety and Serum Phosphorus Lowering Effect of AP-306 in Chronic Kidney Disease Patients Receiving Maintenance Hemodialysis With Hyperphosphatemia
Status:
COMPLETED
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to learn about the following questions in the patients receiving maintenance hemodialysis with elevated blood phosphorus
How much effect AP-306 has assessed by blood phosphorus lowering
How safe and tolerable AP-306 is
Participants will receive either following treatments
AP-306 and
Sevelamer carbonate
How much effect AP-306 has assessed by blood phosphorus lowering
How safe and tolerable AP-306 is
Participants will receive either following treatments
AP-306 and
Sevelamer carbonate
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None